H.R. 1794 establishes a new Abraham Accords Office within the Food and Drug Administration to strengthen regulatory cooperation with countries that have signed the Abraham Accords Declaration (a diplomatic agreement involving several Middle Eastern nations and Israel). The FDA must set up the office within two years, locate it in one of the participating countries, and staff it with FDA personnel to provide technical assistance on drug manufacturing standards and regulatory oversight. The office will help manufacturers in these countries align with FDA requirements and facilitate communication between the FDA and interested parties about product development and research. Within three years of enactment, the Secretary of Health and Human Services must report to Congress on the office's progress, including how many manufacturers have been assisted and what improvements in regulatory coordination have been achieved.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.